^
Association details:
| Biomarker: | CAD-ALK fusion |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
Published date:
01/07/2021
Excerpt:
We identified all cases with RTK fusions in patients with colorectal cancer...The first harbored an ALK-CAD fusion and received sequential crizotinib and alectinib therapy for a total of 7.5 months until developing an ALK L1196Q gatekeeper mutation.
DOI:
10.1158/1078-0432.CCR-20-4073
